Akari Therapeutics Plc

Akari Therapeutics Plc a clinicalstage biopharmaceutical company focuses on developing advanced therapies for autoimmune and inflammatory diseases Its lead product candidate is nomacopan a secondgeneration complement inhibitor that prevents inflammatory and prothrombotic activities including paroxysmal nocturnal hemoglobinuria GuillainBarre syndrome hematopoietic stem cell transplantassociated thrombotic microangiopathy and bullous pemphigoid Akari Therapeutics Plc is based in London the United Kingdom